Dear Bernard, Here are two references:
Rekić, Dinko, Daniel Röshammar, Jackson Mukonzo, and Michael Ashton. "In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype." British journal of clinical pharmacology 71, no. 4 (2011): 536-543. Siccardi, M., L. Almond, A. Schipani, C. Csajka, C. Marzolini, C. Wyen, N. H. Brockmeyer, M. Boffito, A. Owen, and D. Back. "Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro–in vivo extrapolation model." Clinical Pharmacology & Therapeutics 92, no. 4 (2012): 494-502. Kind regards Dinko ________________________________________ From: [email protected] [[email protected]] on behalf of Bernard Ngara [[email protected]] Sent: 01 July 2013 15:52 To: nmusers Subject: [NMusers] efavirenz pbpk input parameters Dear user I am learning modelling and simulation of the efavirenz compound using the In Silico PBPK approach. May you please assist with information on literature where i can obtain input a variety of model input parameters. Thank you Bernard BernardNgara Trainee Biostatistician Africa Institute of Biomedical Science and Technology P. O Box 2294 Harare Zimbabwe +263 772 160 896
